Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) (TA258)
Fast, easy summary view of NICE guidance on 'lung cancer'
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small cell lung cancer
NICE recommends erlotinib as a possible first-line treatment (that is, if you have not had drug treatment before) for some people with locally advanced or metastatic non-small-cell lung cancer (see below).
Who can have erlotinib?
You should be able to have erlotinib if you have a type of locally advanced or metastatic non-small-cell lung cancer that has tested positive for mutations (changes) to EGFR-TK (which stands for epidermal growth factor receptor tyrosine kinase) in the cancer cells.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommended erlotinib because it works as well other treatments available on the NHS, and costs about the same.
- TA258 Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): guidance (web format)
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: lung cancer
This page was last updated: 11 April 2013
- Web format
- Full Guidance (PDF)
- TA258 Erlotinib ar gyfer triniaeth llinell flaen canser yr ysgyfaint sy'n ddatblygedig yn lleol neu'n fetastatig lle nad yw'r celloedd yn fach: deall canllawiau NICE (fformat MS Word)
Information for the public
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.